Figure 3

Role of NRP1 in tumorigenesis is oncogenic KRAS dependent. (A) Western blot analysis showing NRP1 and KRAS levels in doxycycline (Dox)-inducible PANC-1 cells. (B–D) Four groups of SCID mice (n = 8 each) had (i) orthotopic implantation of PANC-1 cells transfected with NRP1 control and KRAS control shRNA or (ii) NRP1 shRNA and KRAS control shRNA; (iii) NRP1 control shRNA and KRAS 236 shRNA (loss of KRAS expression) or (iv) NRP1 shRNA and KRAS 236 shRNA (loss of KRAS and NRP1 expression). All groups received 0.1 μg/mL Dox treatment throughout the entire 8-week study period. (B) Quantification of bioluminescence signals before sacrifice. (C) Ki-67 immunohistochemical staining in each group. (D) Quantification of digital images for Ki-67 staining at ×20 magnification. *P < 0.05 vs control; **P < 0.01 vs control. ^# P < 0.05; ^## P < 0.01 between groups (iii) and (iv).